Mild Autonomous Cortisol Secretion (MACS)
2
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
On Market (1)
Approved therapies currently available
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2026
2027
2028
2029
RecordatiOsilodrostat
Clinical Trials (1)
Total enrollment: 10 patients across 1 trials
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Start: Feb 2026Est. completion: Mar 202910 patients
Phase 4Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 10 patients
1 companies competing in this space